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 Oligonucleotide-peptide conjugates 1-3 were prepared by sequential 
addition of the appropriate Boc-protected amino acids followed by nucleoside 
phosphoramidites in the same support. These molecules are designed to be used 
for triplex formation and for the directed assembly of nanomaterials. The structure 
of the desired oligonucleotide-peptide conjugates was confirmed by mass 
spectrometry on small oligonucleotide-peptide conjugates, by gel electrophoresis 
and by hybridization with complementary oligonucleotide. Oligonucleotides 
carrying the c-myc peptide were specifically recognized by the anti c-myc 
monoclonal antibody. 
 
Introduction.- Oligonucleotide-peptide conjugates are chimeric molecules 
made by oligonucleotides covalently linked to peptide sequences. They are 
produced to transfer some of the biological or/and biophysical properties of 
peptides to synthetic oligonucleotides [1][2]. For example, the introduction of 
peptides into oligonucleotide sequences resulted in the introduction of a higher 
number of multiple nonradioactive labels [3], in improving cellular uptake of 
antisense oligonucleotides [4], in improving binding to DNA [5][6], RNA [7] and 
proteins [8], and in the preparation of  sequence-specific artificial nucleases [9]. 
Recently, we described the introduction of epitope peptide sequences into 
oligonucleotides as nonradioactive labeling system [10]. Specifically, 
oligonucleotides carrying c-myc tag-sequence were prepared using a post-
synthetic conjugation protocol based on the reactivity of the thiol groups. In this 
method, a thiolated oligonucleotide reacted with the c-myc peptide carrying a 
maleimido group. The resulting oligonucleotide-peptide conjugates were 
recognized by an anti-c-myc monoclonal antibody and detection was achieved 
through interaction with a peroxidase-conjugate antibody and a chemiluminiscent 
substrate [10].  
Among the biological molecules, oligonucleotides have been used as 
templates to assemble inorganic nanocrystals. The hybridization properties of the 
oligonucleotides permit the assembly of gold nanoparticles at distances 
determined by the length of the oligonucleotides and also the formation of three-
dimensional networks [11][12][13][14]. In addition, DNA can be metallized to 
form conducting wires between electrodes [15]. These results have rise interest on 
oligonucleotides carrying a second recognition system for the assembly of 
complex nanoparticle networks [16]. Most of the experiments were performed 
using the recognition system of biotin and streptavidin because of the high affinity 
of the biotin-streptavidin interaction [17]. Recently, we described the use of 
branched oligonucleotides carrying biotin to direct one single nanoparticle to the 
middle of a lineal DNA duplex using the biotin-streptavidin system [18-20]. 
Here we described the stepwise synthesis of oligonucleotides carrying the 
c-myc peptide sequence using one single support (schemes 1 and 2). Our aim is 
the preparation of oligonucleotide-peptide conjugates (scheme 1) consisting of 
two sequences connected by a non-DNA material such as hexaethyleneglycol 
(=3,6,9,12,15-pentaoxaheptadecane-1,17-diol) ((EG)6). This type of 
oligonucleotide may be used to assemble nanomaterials as described previously 
[18] [20]. Moreover, the presence of the peptide in these oligonucleotides may 
direct nanoparticles to the middle of the structure using antibodies against the 
peptide. The possibility of using the large diversity of available antibodies and 
their many epitope sequences makes oligonucleotide-peptide conjugates good 
candidates for the directed assembly of complex nanoparticle networks. 
 
Results. - 1. Synthesis of Oligonucleotide-Peptide Conjugates. 
Oligonucleotide-peptide sequences 1-3 (Table 1) were prepared essentially as 
described for the synthesis of oligonucleotides carrying nuclear localization 
peptide (NLS) sequences [21, 22]. First, the peptide sequence was assembled 
using Boc-amino acids on a sarcosyl-polyethyleneglycol-polystyrene (PEG-PS) 
support carrying the 5-aminopentyl linker [23]. The amino group of lysine was 
protected with the trifluoroacetyl (Tfa) group [24]. The carboxylic group of Glu 
and Asp were protected with the 9H-fluoren-9-ylmethyl (Fm) group, and the 
hydroxy group of serine was protected with the acetyl (Ac) group. Once the 
peptide sequence was completed, a linker molecule was added to convert the last 
amino group of the peptide into a hydroxyl group protected by a dimethoxytrityl 
((MeO)2Tr) group. For this purpose, the active ester of the (MeO)2Tr -protected 
derivative of 6-hydroxy hexanoic acid was used. After the addition of the linker, 
aliquots of the support were placed inside the synthesis columns and the assembly 
of the desired oligonucleotide sequences was performed. Phosphoramidites were 
dissolved either in dry CH2Cl2 or dry MeCN. 
First we assembled five thymidines to the peptide support (sequence 1, 
Table 1). Using PEG-PS supports the coupling of the nucleoside 
phosphoramidites may be influence by the solvent used in the reactions. 
Previously, we observed phosphoramidite coupling reactions to be more efficient 
when phosphoramidites were dissolved in dry CH2Cl2 [21, 22] but in this case 
coupling efficiencies were equally high (>98%) using both solvents. A similar 
effect was observed during the synthesis of oligonucleotides carrying trifunctional 
amino acids at the 3’-end [23] and we believe that differences on coupling yields 
are due to the influence of the amino acids on the swelling of the PEG-PS support. 
In general, we observed low coupling yields in MeCN if lysine residues are 
protected with the (9H-fluoren-9-ylmethoxy)carbonyl (Fmoc) group. After the 
removal of the protecting groups with aq. ammonia, the (MeO)2Tr-protected 
oligonucleotide-peptide 1 was purified by reversed phase HPLC using standard 
trityl-on and trityl-off protocols. One major peak was observed that had the 
expected molecular weight.  
The parallel hairpin 2 (Table 1) was prepared using standard 
phosphoramidites for the purine strand and reversed phosphoramidites for the 
assembly of the loop and the pyrimidine strand [25]. The overall yield was 70 % 
and the desired conjugate was isolated from truncated sequences by HPLC using 
trityl-on and trityl-off protocols. The effect on the triplex stability of the presence 
of the c-myc peptide sequence on the hairpin is shown in Table 2. The same 
melting temperatures are observed for triplex formed by peptide-containing 
hairpin (2) as for the triplex formed by the control hairpin without the peptide 
(B22) at pH 4.5 and pH 6.0. This indicates that the peptide sequence at the 
terminal position has no influence on the triplex stability of the hairpin. This was 
expected, because the peptide is attached on a terminal position of the hairpin. The 
same peptide sequence, linked through an internal C residue of an oligonucleotide, 
induces destabilization of the duplex of approximately 10 ºC [10]. 
The branched oligonucleotide 3 (Table 1) having two equal sequences in 
each arm and the c-myc peptide sequence in the middle isolated from the 
oligonucleotide sequences by hexaethyleneglycol molecules was prepared. In 
order to obtain this molecule a symmetric branching molecule [26] was added to 
the peptide-support followed by successive additions of reversed 
phosphoramidites at 0.2 M concentration in dry CH2Cl2 until the desired sequence 
was assembled [19]. Coupling yields, measured by the absorbance of the 
(MeO)2Tr cation released in each detritylation, were around 95%. The desired 
conjugate was isolated from truncated sequences by HPLC obtaining a broad peak 
in the area of the (MeO)2Tr-containing products which was collected. The 
(MeO)2Tr group was removed with acetic acid and the resulting product was 
repurified. Analysis of the purified product by polyacrylamide gel electrophoresis 
show a broad band with less mobility than the corresponding 40 mer as described 
for other oligonucleotide-peptide conjugates [1, 27]. Melting experiments 
performed with duplexes of oligonucleotide 3 with their complementary 
oligonucleotide gave the same melting temperatures when compared with their 
linear analogues (Table 3). 
 
2. Immunodetection of Oligonucleotide-Peptide Conjugates. 
Nonradioactive detection of oligonucleotides carrying the c-myc peptide was 
assayed by on a dot-blot format. Serial dilutions of the oligonucleotide-peptide 
conjugates (from 3 μg) were applied to a nitrocellulose membrane using a 
manifold attached to a suction device. After immobilization of the oligonucleotide 
by UV radiation, the samples were incubated with an anti-c-myc monoclonal 
antibody [28], followed by incubation with a secondary antibody conjugated to 
horseradish peroxidase, and developed with a chemiluminescent substrate. Fig. 2 
shows the autoradiography of the detection of oligonucleotides carrying the c-myc 
peptide prepared in this work (Lanes 2-4) as well as several controls such as 
peptide c-myc alone (Lane 1), oligonucleotide without peptide (Lane 5) and 
oligonucleotide carrying a peptide non-related with c-myc (Lane 6). Positive dots 
were obtained for the oligonucleotides carrying the c-myc peptide. Peptide c-myc 
alone and pentathymidine sequence 1 gave a positive dot only at the highest 
concentration. This is due to low efficiency of the attachment of these compounds 
to the nitrocellulose membrane. Oligonucleotide sequences 2 and 3 gave a 
positive dot up to 90-180 ng. Control oligonucleotides without peptide and with a 
non-related peptide gave no signal.  
It is important to remark that the detection limit on the oligonucleotide-
peptide conjugates prepared in this work using the stepwise method is similar to 
the conjugates prepared by postsynthetic conjugation [10]. This confirm the 
integrity of the peptide during oligonucleotide synthesis and ammonia 
deprotection. Although mass spectrometry gave the expected mass, this method 
will not detect racemization of the amino acids. On the contrary the recognition of 
the antibody to the oligonucleotide-peptide conjugates is a good proof of the 
correct quirality of the amino acids.   
 
Discussion.  The ability to control the assembly of nanomaterials from 
well-defined units is a key step that is expected to allow the exploitation of the 
technological potential of these materials. The use of the hybridisation properties 
of oligonucleotides is a promising approach [11][12][13][14][16][17][18]. Our 
aim in this paper was the synthesis of oligonucleotides carrying peptide epitopes. 
This type of chimeric molecule carry two well-defined recognition systems: the 
natural affinity to their complementary DNA sequence and the antibody-epitope  
interaction. Although this may be achieved easily using small ligands such as 
introducing biotin in oligonucleotides, the number of available epitope-antibody 
recognition systems is practically unlimited. So, a larger molecular diversity can 
be obtained with oligonucleotide-peptide conjugates.  
We show that oligonucleotide carrying the c-myc peptide as model 
sequence for a peptide epitope could be prepared by sequential addition of Boc-
amino acids protected with base labile groups in their side chains followed by the 
addition of phosphoramidites. Moreover, complex oligonucleotides such as 
branched oligonucleotides with two identical arms carrying the c-myc peptide at 
the central position are amenable to chemical synthesis. This new class of 
oligonucleotides have potential interest as templates for the assembly of 
nanomaterials  
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Experimental Part 
 
General. Phosphoramidites and ancillary reagents used during 
oligonucleotide synthesis were from Applied Biosystems (PE Biosystems Hispania 
S.A., Spain), Cruachem Ltd. (Scotland), and Glen Research Inc. (USA). Amino 
acid derivatives were from Bachem (Switzerland) and Novabiochem 
(Switzerland). The rest of the chemicals were purchased from Aldrich, Sigma or 
Fluka (Spain). Long-chain-alkyl-amine controlled-pore glass (LCAA-CPG) was 
purchased from CPG, Inc. (New Jersey, USA). Amino-polyethyleneglycol-
polystyrene (PEG-PS) was purchased from PerSeptive (now Applied Biosystems, 
USA). Solvents were from S.D.S. (France). NAP-10 columns (Sephadex G-25) 
were purchased from Pharmacia Biotech. Oligonucleotide sequences were 
synthesized on a Applied Biosystems-392 DNA synthesizer (Applied Biosystems, 
USA). UV-Visible spectra and melting temperatures: Shimadzu UV-2101PC 
spectrophotometer equipped with a temp. controller SPR-8. Mass spectra (matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF), and 
electrospray were provided by the mass spectrometry service at the University of 
Barcelona. 
 
Synthesis of Oligonucleotide-Peptide Conjugates. The c-myc tag sequence 
(N-terminal Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn C-terminal) was 
assembled on a 0.19 mmol scale using a homemade manual synthesizer and 
amino-PEG-PS (0.19 mmol/g) as the solid support. First, Fmoc-sarcosine was 
coupled using Ph3P and 2,2’-dithiobis[5-nitropyridine] as coupling agents [29]. 
Then, the handle butanedioic acid mono [5-(MeO)2Tr-aminopent-1-yl] ester was 
coupled to the resin as described elsewhere [21-23]. The loading of the support, as 
measured by the absorbance of the (MeO)2Tr cation, was 0.1 mmol/g. The peptide 
sequence was assembled on the 5-aminopentyl-succinyl-sarcosyl-PEG-PS support 
using Boc-chemistry [21-23]. Protection of the side chains was as follows: The ε-
amino group of lysine was protected with the Tfa group, the carboxyl groups of 
glutamic and aspartic acid were protected with the Fm group, and the hydroxyl 
group of serine was protected with the Ac group. The peptide was elongated in 
N,N-dimethylformamide (DMF) using a 5-fold excess of Boc-amino acid, 10-fold 
excess of EtN(i-Pr)2, and 5-fold excess of [(1H-benzotriazol-1-
yl)oxy]tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) for 1 h at 
room temperature. In order to remove the Boc group, the support was treated with 
a 30% CF3COOH soln. in CH2Cl2 for 30 min and neutralized with EtN(i-Pr)2-
CH2Cl2 (1:19). After the assembly of the peptide sequence an extra alanine and a 
derivative of 6-hydroxyhexanoic acid were added as spacers to separate the 
peptide sequence from the oligonucleotide and to convert the last amino group to 
a hydroxyl group [21-23]. The assembly of the oligonucleotide chain requires the 
presence of the hydroxyl group. The 6-hydroxyhexanoic linker carried a 
(MeO)2Tr group for protection of the hydroxyl group and it was a 4-nitrophenyl 
ester (5-fold excess in DMF for 1 h). Characterization of the peptide support was 
performed by treatment of an aliquot with conc. ammonia and analysis of the 
resulting product by mass spectrometry. MALDI-TOF of the resulting peptide: 
1588.4 [M+H]+; calc. for C69H118 N16O26:1587.6. 
 
Synthesis of Oligonucleotide-Peptide Sequences 1 and 2. Oligonucleotide 
sequences were assembled on a 1 μmol scale. The phosphoramidites were 
dissolved either in dry CH2Cl2 or in dry MeCN, giving 0.1 M solutions (using 
either reverse phosphoramidites for the pyrimidine chain growth or standard 
phosphoramidites for the purine chain elongation). The coupling time was 
increased to 5 min, capping and oxidation times to 1 min and the detritylation step 
to 2 min. Coupling yields were >95%. The last (MeO)2Tr protecting group was 
not removed. After the assembly, some of the protecting groups (Fmoc, Fm, 
CH2CH2CN) were removed with a 0.5M soln. of 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) in MeCN [21-23]. The conjugates were liberated from the solid 
support by conc. ammonia (with drops of dioxane) in an overnight treatment at 
55ºC, with concomitant removal of the nucleobase protecting groups. After 
filtration of the solid supports, the solutions were evaporated to dryness, the 
residues were dissolved in water and the conjugates were purified using standard 
two-step HPLC. Yields after purification. 1: 8 OD units, 2: 9 OD units. 3: 34 OD 
units. Electrospray of 1: 621.29 [M+Na-6H]5-, 775.74 [M+Na-5H]4-, 1034.63 
[M+Na-4H]3-,  and 1585.41 [M+Na-3H]2- giving a molecular weight of 3108.2; 
calc. for C119H183 N26O61P5 3108.4. MALDI-TOF of 2: 9859.29 [M+17Na-16H]+; 
calc. for C313H410 N105Na17O190 P25: 9847.41. 
 
Synthesis of Oligonucleotide-Peptide Sequence 3. After the addition of 6-
hydroxyhexanoic acid, the symmetric doubler phosphoramidite (Cruachem or 
Glen Research) was added. The oligonucleotide sequence was then assembled 
using reversed phosphoramidites. A hexaethyleneglycol molecule (Cruachem or 
Glen Research) was added between the symmetric doubler and the first 
nucleotide. For the synthesis of the oligonucleotide part we used a special cycle 
with the following changes: increased coupling time (5 min), and double coupling 
using double concentration (0.2 M) of phosphoramidites. In addition 
phosphoramidites were dissolved in dry CH2Cl2. Scale of synthesis : 1 μmol. The 
last (MeO)2Tr group was not removed to facilitate HPLC purification. After the 
assembly, the support was treated with DBU [21-23] and the conjugate was 
liberated from the solid support by concentrated ammonia (with drops of dioxane) 
in an overnight treatment at 55ºC. The conjugate was purified by HPLC obtaining 
a broad peak in the area of the (MeO)2Tr-containing products, which was 
collected. The (MeO)2Tr was removed with acetic acid and the resulting product 
was repurified obtaining 44 O.D. units at 260 nm (1.3 mg). The homogeneity of 
the purified product was checked by PAGE (data not shown). 
 
Melting Experiments. Melting experiments were performed as follows. 
Solutions of equimolar amounts of the appropriate oligonucleotides were mixed 
either in a soln. containing 0.15M NaCl, 0.05M Tris·HCl buffer of pH 7.5 (in 
experiments related with duplex formation) or in a soln. containing 1M NaCl and 
0.1M sodium phosphate / citric acid buffer of pH 4.5 or pH 6.0 (in experiments 
related with triplex formation). The DNA concentration was determined by UV 
absorbance measurements (260 nm) at 90 ºC, using for the DNA coil state the 
following extinction coefficients: 7500, 8500, 12500, and, 15000 M-1 cm-1 for C, 
T, G, and, A, respectively. The solutions were heated to 90 ºC, allowed to cool 
slowly to room temperature, and stored at 4ºC until UV was measured. UV 
absorption spectra and melting experiments (absorbance vs temperature) were 
recorded in 1 cm path-length cells using a spectrophotometer, with a temperature 
controller and a programmed temperature increase rate of 0.5 ºC/min. Melting 
curves were recorded at 260 nm and melting temperatures were measured at the 
maximum of the first derivatives of the melting curves. Results: see Table 2 and 
Table 3. 
 
Immunodetection of the Oligonucleotide-Peptide Conjugates. Serial 
dilutions (from 3µg) of the oligonucleotide-peptide conjugates dissolved in water 
were applied to a nitrocellulose membrane (0.2µm, BioRad) using a manifold 
attached to a suction device. After drying at 70 ºC for 30minutes, the membrane 
was UV cross-linked for 2.5 minutes. The membrane was blocked with PBS 
containing 1% Tween 20 for 1h at room temperature and incubated with culture 
supernatant from anti-c-myc murine hybridoma clone 9E10 (24.6mg/ml, [28]) for 
1h at room temperature. After washing twice with PBS containing 0.1%Tween-20 
for 15 minutes, the membrane was incubated with a horseradich peroxidase-
conjugated goat anti-mouse antibody (Jackson, 0.9 mg/mL) at a 1:20000 dilution 
for 1h. Finally, after several washes with PBS containing Tween-20, the 
membrane was developed in ECL (Amersham) and exposed to X-ray film. 
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 Table 1: Sequences of the Synthesized Oligonucleotide-Peptide Conjugates 
 
 Sequencea) 
1 5’TTTTT-3’-hexyl-CONH-AEQKLISEEDLN-CONH-(CH2)5-OH 
2 3’-TCTCCTCCTTC-TTTT-5’-5’GAAGGAGGAGA-3’-hexyl-CONH-AEQKLISEEDLN-
CONH-(CH2)5-OH 
3 3’-CGTAACTCGCTACGTCCGTC-(EG)6-(bpp-hexyl-CONH-AEQKLISEEDLN-CONH-
(CH2)5-OH)-(EG)6-CTGCCTGCATCGCTCAATGC-3’ 
a)(EG)6: hexaethyleneglycol, bpp: [-PO3-O(CH2)4-CONH-CH2]2-CHOPO3-  
 
Table 2. Melting Temperatures (Tm) of Triplexes Formed by Oligonucleotide 2 
and a Control Sequence.  
 
Triplex  Tm [º]a) 
pH 4.5 
Tm [º]a) 
pH 6.0 
B22 + S11WC 
 
63 45 
2 + S11WC 
 
64 45 
a) S11WC: 5’-CTTCCTCCTCT-3’; B22: 3’-AGAGGAGGAAG-5’-(EG)6-5’-
CTTCCTCCTCT 3’, 0.1M sodium phosphate and citric acid, 1M NaCl, error 
in Tm is ±1 º. 
 
3'-CTTCCTCCTCT-5'
GAAGGAGGAGA-3'
: : : : : : : : : : :
CTTCCTCCTCT-3'
(EG)6
3'-CTTCCTCCTCT-5'
GAAGGAGGAGA-PEPTIDE
: : : : : : : : : : :
CTTCCTCCTCT-3'
T
T
T
 Table 3: Melting Temperatures (Tm) of Duplexes Formed by Oligonucleotide 3 
and the Linear Control Sequence.  
 
Oligonucleotide Tm [º]a) 
3 71 
5’-CTGCCTGCATCGCTCAATGC-3’ 72 
a) Complementary sequence: 3’-GAC GGA CGT AGC GAG TTA CG-5’, 0.050M 
Tris·HCl, 0.15M NaCl, pH 7.5, error in Tm is ±1 º. 
 
  
LEGENDS 
Scheme 1: Schematic Representation of Oligonucleotide-Peptide Conjugates 
Described in this Paper. 
 
Scheme 2. Outline of the Synthesis of the Oligonucleotide-Peptide Conjugate 3.  
 
Fig. 1: HPLC profiles of (MeO)2Tr-containing oligonucleotides 1 (a) and 2 (b). 
Truncated sequences without (MeO)2Tr groups had a retention time of less than 5 
minutes. Benzamide eluted at 7-8 minutes. The desired oligonucleotide-peptide 
conjugate with the (MeO)2Tr group eluted at 10-14 minutes.  
 
Fig. 2: Immunodetection of Oligonucleotide-Peptide Conjugates. Serial ½ 
dilutions from 3µg of oligonucleotide-peptide conjugates were applied to the blot 
and immunodetection performed with anti c-myc antibody. Lane 1, peptide c-myc; 
Lane 2, oligonucleotide 2; Lane 3, oligonucleotide 1; Lane 4, oligonucleotide 3; 
Lane 5, oligonucleotide control containing 24 bases without peptide; Lane 6, 
dodecamer carrying the nuclear localization sequence (QAKKKKLDK); Lane 7, 
blank. 
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PEPTIDE SYNTHESIS, Boc-chemistry
OLIGONUCLEOTIDE SYNTHESIS, reversed 5'->3'
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